Monthly Archives: September 2011

Corporate venture capital’s rise to prominence in biotech over the past few years is now a well worn subject.  It was yet again debated this week at the Windhover PSA meeting, in part triggered by the recent widely-covered launch of

Amidst talk of the need for renewed economic stimulus and the desire for America to invest in innovative industries, I thought I’d highlight two practical tax policy ideas for how to accelerate biotech sector growth: enabling NOL tradability and creating

The sustainability of the biopharma sector depends on a continual flow of new startups to both feed Big Pharma’s pipelines and to create the next generation of emerging mid-cap companies.  At the BioPharma America conference this week, several panelists asserted

Earlier this week the Startup Genome project released a report on the DNA of internet startups.  Essentially what attributes lead to success or failure.  One of the things they found was that 74% of startups failed because of “premature scaling”.